Pregnant and lactating woman should not use L-carnitine as the safety is unknown.
Even though epidemiology may be of some help in orientating the clinician and even though some lesions may confidently be diagnosed on clinical grounds alone, the definitive diagnosis usually requires histopathologic evaluation
Lets look at who stands to benefit the most
Can you switch between treatments
How I Approach This With Patients Currently on GLP-1 Medication For patients actively using GLP-1 medications who come to me proactively, before significant skin changes have developed, I focus the conversation on prevention and monitoring rather than correction: supporting skin's structural health through appropriate topical actives, discussing realistic expectations about the pace of weight loss and its relationship to skin's ability to adapt, and establishing a baseline so we can track changes over time rather than only reacting once laxity has become significant
Nonetheless, these mechanisms have not been consistently replicated in humans, particularly in individuals with severely reduced left ventricular function who may not benefit [72, 73], or may even being harmed [74], from treatment with GLP-1RAs
